A Phase 2 interventional study of lenalidomide and Placebo in Complex Regional Pain Syndrome, Type I, sponsored by Celgene Corporation. Terminated at 27 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-28.
Sponsored by Celgene Corporation (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Reflex Sympathetic Dystrophy with a site in United States — 2 open to participants now, 2 under way, 1 of them phase 3. Reflex Sympathetic Dystrophy · United States.
Among the 15 studies in Reflex Sympathetic Dystrophy with a site in United States, this one is the 5th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2005, is one of 3 in phase 2, and was the 4th registered.
43 studies on the registry are indexed under Reflex Sympathetic Dystrophy; 4 are open to participants now.
Browse Reflex Sympathetic Dystrophy studies →2 of the 15 studies in Reflex Sympathetic Dystrophy with a site in United States are open now. Recruiting first, the newest first:
Ambros Therapeutics, Inc. · Sites in United States
Ages 18+
Ambros Therapeutics, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 4 Reflex Sympathetic Dystrophy studies recruiting now, 3 set no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 6
First in 1992; this study’s year is marked. 1 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 184 is above the median of 48 across 35 interventional studies indexed under Reflex Sympathetic Dystrophy.
Median enrollment 113 across the 12 interventional studies, 273 across the 3 observational. Of the 11 that completed or were terminated, 7 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 15 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene Corporation, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene Corporation is the lead sponsor of 52 studies on the registry; none are open to participants now.
Bristol-Myers Squibb has 2 studies filed under Reflex Sympathetic Dystrophy — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Reflex Sympathetic Dystrophy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this multicenter, double-blind, placebo-controlled study is to evaluate the efficacy and safety of Lenalidomide in adult subjects with Complex Regional Pain Syndrome (CRPS) Type 1.
This is a multicenter, double-blind, placebo-controlled study in adult subjects with Complex Regional Pain Syndrome (CRPS) Type 1.
One hundred eighty (180) subjects diagnosed with unilateral CRPS Type 1 will be enrolled and randomized to receive orally either 10 mg/day of lenalidomide or placebo (90 subjects per treatment arm). For each subject, the study consists of three phases: Pre-randomization Phase (2 weeks), Treatment Phase (12 weeks) and Extension Phase where subjects have the opportunity to receive lenalidomide treatment as long as a benefit is derived from the drug. Subjects who complete all 12 weeks of the treatment phase may be eligible to receive lenalidomide in the extension phase. Subject may continue in the extension phase as long as a benefit is derived from the drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The presence of any of the following will exclude a subject from study enrollment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10 mg/day lenalidomide orally for up to 12 weeks in the double-blind treatment period. Participants who completed double-blind treatment had the option of continuing on lenalidomide in the open-label extension period for as long as benefit was derived from the drug or until study closure.
Drug: lenalidomide
Placebo orally for up to 12 weeks in the double-blind treatment period. Participants who completed double-blind treatment had the option of crossing over to lenalidomide 10mg in the open-label extension period for as long as benefit was derived from the drug or until study closure.
Drug: Placebo
Two 5 mg capsules taken one time per day
Also known as: Revlimid, CC-5013
Two placebo capsules taken one time per day
Percentage of Participants Who Have a >= 30% Reduction (Improvement) in the Complex Regional Pain Syndrome (CRPS) Pain Intensity Numeric Rating Scale (PI-NRS) Score From Baseline to the Last Assessment
Participants rated the intensity of pain in the CRPS-affected limb twice each day in a diary. The PI-NRS is an eleven point scale with 0=no pain and 10=worst pain imaginable. Responders are participants who completed 12 weeks of treatment and their week 12 PI-NRS score showed at least a 30% improvement from baseline. Participants who did not complete 12 weeks of treatment are considered non-responders.
Time frame: Day 0, Week 12
Change From Baseline in the Total Score of the Short Form McGill Pain Questionnaire (SF-MPQ) at Week 12
Short Form McGill Pain Questionnaire (SF-MPQ) is comprised of 15 pain qualities that are rated by the participant on a 4 point scale with 0=none and 3=severe. The scale for the Total Score is 0-45. Week 12 values are compared to baseline values. Negative changes indicate improvement in level of pain.
Time frame: Day 0, week 12
Change From Baseline in the Complex Regional Pain Syndrome (CRPS) Pain Intensity Numeric Rating Scale (PI-NRS) Score Using Averaged Morning and Evening Readings at Week 12
Participants rated the intensity of pain in the CRPS-affected limb twice each day in a diary. Morning and evening scores are averaged. The PI-NRS is an eleven point scale with 0=no pain and 10=worst pain imaginable. Week 12 values are compared to baseline values. Negative changes indicate improvement in level of pain.
Time frame: Day 0, week 12
Change From Baseline in the Morning Complex Regional Pain Syndrome (CRPS) Pain Intensity Numeric Rating Scale (PI-NRS) Score at Week 12
Participants rated the intensity of pain in the CRPS-affected limb twice each day in a diary. The PI-NRS is an eleven point scale with 0=no pain and 10=worst pain imaginable. The morning pain ratings at baseline and Week 12 are compared. Negative changes indicate improvement in level of pain.
Time frame: Day 0, week 12
Change From Baseline in the Evening Complex Regional Pain Syndrome (CRPS) Pain Intensity Numeric Rating Scale (PI-NRS) Score at Week 12
Participants rated the intensity of pain in the CRPS-affected limb twice each day in a diary. The PI-NRS is an eleven point scale with 0=no pain and 10=worst pain imaginable. The evening pain ratings at baseline and Week 12 are compared. Negative changes indicate improvement in level of pain.
Time frame: Day 0, week 12
Change From Baseline in Daily Sleep Assessment Average Score at Week 12
Participants rated how much CRPS pain interfered with their sleep each day in a diary. The Sleep Assessment uses an eleven point scale for four questions. Questions concern ability to fall asleep, ability to stay asleep, how refreshed the participant feels upon waking and how alert the participant is during the day. All use a scale of 0-10, where the higher number is the positive response (e.g. 0=Pain completely interferes with sleep and 10=Pain does not interfere). The mean of all four responses was calculated if at least 3 of the 4 questions had a value. Week 12 values are compared to baseline values. Positive change values indicate improvement.
Time frame: Day 0, week 12
Change From Baseline in Activity Level Rating Using a Numeric Rating Scale (NRS) at Week 12
Participants rated how the activity level on a given day compares with their activity level prior to the start of treatment. A seven-point scale is used with -3=much worse and +3=much better. Positive change values indicate improvement.
Time frame: Day 0, week 12
Change From Baseline in Participant Assessment of CRPS Symptoms Total Score at Week 12
Participants rated twelve CRPS symptoms using a four-point rating scale in which 1=the most positive outcome and 4= the most negative outcome for a total scale of 12-48. Week 12 values are compared to baseline values. Negative change values indicate improvement.
Time frame: Day 0, week 12
Change From Baseline in "Mechanically Evoked" (Allodynia) Numeric Rating Scale (NRS) Score at Week 12
The investigator rated the degree of allodynia on both the CRPS-affected limb on an eleven-point scale where 0=no pain and 10=worst pain imaginable. This outcome compares the baseline values for the CRPS affected-limb to the values at week 12. Negative change values indicate improvement.
Time frame: Day 0, week 12
Difference in Allodynia Rating Between the CRPS-affected Limb and the Normal Limb at Week 12
The investigator rated the degree of allodynia on both the CRPS-affected limb and the normal (or less-affected) limb on an eleven-point scale where 0=no pain and 10=worst pain imaginable. This outcome compares the values for the CRPS affected-limb to the normal limb at week 12.
Time frame: Week 12
Change From Baseline in the Brief Pain Inventory (BPI) Total Score at Week 12
Participants completed the Brief Pain Inventory which asks twelve questions that are rated on an eleven-point scale in which 0=most positive outcome and 10=the most negative outcome for a total scale of 0-120. BPI contains questions that concern the level of pain over the last week and the level of pain right now, the extent to which pain interfered with sleep, normal activities, ability to work, relationships, walking etc. Week 12 values are compared to baseline values. Negative change values indicate improvement.
Time frame: Day 0, week 12
Change From Baseline in the Profile of Mood States (POMS) at Week 12
Participants completed the Profile of Mood States questionnaire that asks participants to rate how each of 65 words reflected their mood in the past week on a 5-point scale with 0=not at all and 4=extremely for a total scale of 0-260. Week 12 values are compared to baseline values. Negative change values indicate improvement.
Time frame: Day 0, week 12
Patient Global Impression of Change (PGIC) at Week 12
The Patient Global Impression of Change asks the question: Overall, how would you rate your CRPS condition since the start of study drug? Answers are represented on a seven-point scale with -3=much worst and +3=much better.
Time frame: Week 12
Participants Who Had a Change to CRPS Pain Medication During the Treatment Period
Participants who had any change in CRPS medication during the double-blind treatment period (up to week 12) are summarized. Changes include additions, discontinuations or dosage change of CRPS medication(s).
Time frame: Day 1 to week 12
Change From Baseline in the Maximal Composite Motor Nerve Conduction Velocity at Week 12
An electrophysiological evaluation using standard electrophysiological and electromyography to measure the speed and extent of nerve conduction. Week 12 values are compared to baseline values for maximal motor nerve conduct velocity.
Time frame: Day 0, week 12
Change From Baseline in the Maximal Composite Sensory Nerve Conduction Velocity at Week 12
An electrophysiological evaluation using standard electrophysiological and electromyography to measure the speed and extent of nerve conduction. Week 12 values are compared to baseline values for maximal sensory nerve conduct velocity.
Time frame: Day 0, week 12
Participants With Treatment-Emergent Adverse Events in the Double-Blind Period or the Extension Period
Counts of study participants who had adverse events (AEs) while treated in either the Double-blind or Extension Periods. The NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0 was used by the investigator to grade the severity of the AEs: Grade 1=Mild AE, Grade 2=Moderate AE, Grade 3=Severe AE, Grade 4=Life-threatening or disabling AE, Grade 5=Death related to AE. AEs are also summarized by whether they were serious, related to treatment and whether the AE caused treatment to be altered. A serious AE (SAE) was any event that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or congenital anomaly/birth defect or was an important medical event could have jeopardized the patient's safety or required medical or surgical intervention to prevent one of the outcomes listed above.
Time frame: Day 1 up to week 158
| Milestone | Lenalidomide | Placebo to Lenalidomide |
|---|---|---|
| Started | 90 | 94 |
| Safety and itt population | 87 | 93 |
| Completed | 68 | 79 |
| Not completed | 22 | 15 |
| Withdrew: Adverse event | 14 | 5 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Lost to follow-up | 2 | 3 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Other | 0 | 4 |
| Withdrew: Withdrew prior to treatment | 3 | 1 |
| Milestone | Lenalidomide | Placebo to Lenalidomide |
|---|---|---|
| Started | 64 | 78 |
| Completed | 19 | 29 |
| Not completed | 45 | 49 |
| Withdrew: Adverse event | 10 | 19 |
| Withdrew: Lack of efficacy | 19 | 11 |
| Withdrew: Withdrawal by subject | 9 | 6 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Protocol violation | 2 | 2 |
| Withdrew: Other | 4 | 10 |
Participants rated the intensity of pain in the CRPS-affected limb twice each day in a diary. The PI-NRS is an eleven point scale with 0=no pain and 10=worst pain imaginable. Responders are participants who completed 12 weeks of treatment and their week 12 PI-NRS score showed at least a 30% improvement from baseline. Participants who did not complete 12 weeks of treatment are considered non-responders.
| percentage of participants | Lenalidomide | Placebo to Lenalidomide |
|---|---|---|
| Responders | 16.1 | 16.1 |
| Non-responders | 83.9 | 83.9 |
Short Form McGill Pain Questionnaire (SF-MPQ) is comprised of 15 pain qualities that are rated by the participant on a 4 point scale with 0=none and 3=severe. The scale for the Total Score is 0-45. Week 12 values are compared to baseline values. Negative changes indicate improvement in level of pain.
| units on a scale | Lenalidomide | Placebo to Lenalidomide |
|---|---|---|
| Change From Baseline in the Total Score of the Short Form McGill Pain Questionnaire (SF-MPQ) at Week 12 | -5.2 ± 9.15 | -3.0 ± 9.37 |
Participants rated the intensity of pain in the CRPS-affected limb twice each day in a diary. Morning and evening scores are averaged. The PI-NRS is an eleven point scale with 0=no pain and 10=worst pain imaginable. Week 12 values are compared to baseline values. Negative changes indicate improvement in level of pain.
| units on a scale | Lenalidomide | Placebo to Lenalidomide |
|---|---|---|
| Change From Baseline in the Complex Regional Pain Syndrome (CRPS) Pain Intensity Numeric Rating Scale (PI-NRS) Score Using Averaged Morning and Evening Readings at Week 12 | -0.6 ± 1.65 | -0.4 ± 1.50 |
Participants rated the intensity of pain in the CRPS-affected limb twice each day in a diary. The PI-NRS is an eleven point scale with 0=no pain and 10=worst pain imaginable. The morning pain ratings at baseline and Week 12 are compared. Negative changes indicate improvement in level of pain.
| units on a scale | Lenalidomide | Placebo to Lenalidomide |
|---|---|---|
| Change From Baseline in the Morning Complex Regional Pain Syndrome (CRPS) Pain Intensity Numeric Rating Scale (PI-NRS) Score at Week 12 | -0.6 ± 1.67 | -0.4 ± 1.53 |
Participants rated the intensity of pain in the CRPS-affected limb twice each day in a diary. The PI-NRS is an eleven point scale with 0=no pain and 10=worst pain imaginable. The evening pain ratings at baseline and Week 12 are compared. Negative changes indicate improvement in level of pain.
| units on a scale | Lenalidomide | Placebo to Lenalidomide |
|---|---|---|
| Change From Baseline in the Evening Complex Regional Pain Syndrome (CRPS) Pain Intensity Numeric Rating Scale (PI-NRS) Score at Week 12 | -0.6 ± 1.69 | -0.4 ± 1.53 |
Participants rated how much CRPS pain interfered with their sleep each day in a diary. The Sleep Assessment uses an eleven point scale for four questions. Questions concern ability to fall asleep, ability to stay asleep, how refreshed the participant feels upon waking and how alert the participant is during the day. All use a scale of 0-10, where the higher number is the positive response (e.g. 0=Pain completely interferes with sleep and 10=Pain does not interfere). The mean of all four responses was calculated if at least 3 of the 4 questions had a value. Week 12 values are compared to baseline values. Positive change values indicate improvement.
| units on a scale | Lenalidomide | Placebo to Lenalidomide |
|---|---|---|
| Change From Baseline in Daily Sleep Assessment Average Score at Week 12 | 0.7 ± 1.48 | 0.7 ± 1.42 |
Participants rated how the activity level on a given day compares with their activity level prior to the start of treatment. A seven-point scale is used with -3=much worse and +3=much better. Positive change values indicate improvement.
| units on a scale | Lenalidomide | Placebo to Lenalidomide |
|---|---|---|
| Change From Baseline in Activity Level Rating Using a Numeric Rating Scale (NRS) at Week 12 | 0.1 ± 1.08 | 0.2 ± 1.09 |
Participants rated twelve CRPS symptoms using a four-point rating scale in which 1=the most positive outcome and 4= the most negative outcome for a total scale of 12-48. Week 12 values are compared to baseline values. Negative change values indicate improvement.
| units on a scale | Lenalidomide | Placebo to Lenalidomide |
|---|---|---|
| Change From Baseline in Participant Assessment of CRPS Symptoms Total Score at Week 12 | -2.4 ± 6.27 | -1.4 ± 5.83 |
The investigator rated the degree of allodynia on both the CRPS-affected limb on an eleven-point scale where 0=no pain and 10=worst pain imaginable. This outcome compares the baseline values for the CRPS affected-limb to the values at week 12. Negative change values indicate improvement.
| units on a scale | Lenalidomide | Placebo to Lenalidomide |
|---|---|---|
| Change From Baseline in "Mechanically Evoked" (Allodynia) Numeric Rating Scale (NRS) Score at Week 12 | -0.8 ± 2.38 | -0.1 ± 2.64 |
The investigator rated the degree of allodynia on both the CRPS-affected limb and the normal (or less-affected) limb on an eleven-point scale where 0=no pain and 10=worst pain imaginable. This outcome compares the values for the CRPS affected-limb to the normal limb at week 12.
| units on a scale | Lenalidomide | Placebo to Lenalidomide |
|---|---|---|
| Difference in Allodynia Rating Between the CRPS-affected Limb and the Normal Limb at Week 12 | 3.7 ± 3.23 | 4.1 ± 3.41 |
Participants completed the Brief Pain Inventory which asks twelve questions that are rated on an eleven-point scale in which 0=most positive outcome and 10=the most negative outcome for a total scale of 0-120. BPI contains questions that concern the level of pain over the last week and the level of pain right now, the extent to which pain interfered with sleep, normal activities, ability to work, relationships, walking etc. Week 12 values are compared to baseline values. Negative change values indicate improvement.
| units on a scale | Lenalidomide | Placebo to Lenalidomide |
|---|---|---|
| Change From Baseline in the Brief Pain Inventory (BPI) Total Score at Week 12 | -4.8 ± 13.03 | -3.7 ± 12.22 |
Participants completed the Profile of Mood States questionnaire that asks participants to rate how each of 65 words reflected their mood in the past week on a 5-point scale with 0=not at all and 4=extremely for a total scale of 0-260. Week 12 values are compared to baseline values. Negative change values indicate improvement.
| units on a scale | Lenalidomide | Placebo to Lenalidomide |
|---|---|---|
| Change From Baseline in the Profile of Mood States (POMS) at Week 12 | -9.6 ± 33.99 | -4.5 ± 33.91 |
The Patient Global Impression of Change asks the question: Overall, how would you rate your CRPS condition since the start of study drug? Answers are represented on a seven-point scale with -3=much worst and +3=much better.
| units on a scale | Lenalidomide | Placebo to Lenalidomide |
|---|---|---|
| Patient Global Impression of Change (PGIC) at Week 12 | 0.2 ± 1.45 | 0.2 ± 1.41 |
Participants who had any change in CRPS medication during the double-blind treatment period (up to week 12) are summarized. Changes include additions, discontinuations or dosage change of CRPS medication(s).
| participants | Lenalidomide | Placebo to Lenalidomide |
|---|---|---|
| Change to CRPS medication(s) | 11 | 7 |
| No change to CRPS medication | 76 | 86 |
An electrophysiological evaluation using standard electrophysiological and electromyography to measure the speed and extent of nerve conduction. Week 12 values are compared to baseline values for maximal motor nerve conduct velocity.
| meters/second | Lenalidomide | Placebo to Lenalidomide |
|---|---|---|
| Change From Baseline in the Maximal Composite Motor Nerve Conduction Velocity at Week 12 | 0.3 ± 1.56 | 0.1 ± 2.14 |
An electrophysiological evaluation using standard electrophysiological and electromyography to measure the speed and extent of nerve conduction. Week 12 values are compared to baseline values for maximal sensory nerve conduct velocity.
| meters/second | Lenalidomide | Placebo to Lenalidomide |
|---|---|---|
| Change From Baseline in the Maximal Composite Sensory Nerve Conduction Velocity at Week 12 | 1.2 ± 3.51 | 0.1 ± 3.41 |
Counts of study participants who had adverse events (AEs) while treated in either the Double-blind or Extension Periods. The NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0 was used by the investigator to grade the severity of the AEs: Grade 1=Mild AE, Grade 2=Moderate AE, Grade 3=Severe AE, Grade 4=Life-threatening or disabling AE, Grade 5=Death related to AE. AEs are also summarized by whether they were serious, related to treatment and whether the AE caused treatment to be altered. A serious AE (SAE) was any event that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or congenital anomaly/birth defect or was an important medical event could have jeopardized the patient's safety or required medical or surgical intervention to prevent one of the outcomes listed above.
| participants | Lenalidomide | Placebo to Lenalidomide |
|---|---|---|
| Adverse event (AE) | 83 | 85 |
| Serious adverse event (SAE) | 12 | 16 |
| AE leading to study drug discontinuation | 29 | 29 |
| AE leading to dose reduction or interruption | 10 | 8 |
| Treatment-related AE | 68 | 66 |
| Treatment-related SAE | 1 | 5 |
| Grade 2 or higher AE | 63 | 68 |
| Grade 3 or higher AE | 15 | 18 |
Collected over Day 1 up to week 158, covering both the double-blind treatment and extension periods.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lenalidomide | — | 12/87 (13.8%) | 77/87 (88.5%) |
| Placebo to Lenalidomide | — | 16/93 (17.2%) | 72/93 (77.4%) |
| Event | Lenalidomide | Placebo to Lenalidomide |
|---|---|---|
| Joint sprainInjury, poisoning and procedural complications | 2/87 | 0/93 |
| Pregnancy NOSPregnancy, puerperium and perinatal conditions | 2/87 | 0/93 |
| Deep vein thrombosisVascular disorders | 1/87 | 2/93 |
| Foot fractureInjury, poisoning and procedural complications | 1/87 | 0/93 |
| ThrombosisVascular disorders | 1/87 | 0/93 |
| Blood human chorionic gonadotropin positiveInvestigations | 1/87 | 0/93 |
| Blood potassium decreasedInvestigations | 1/87 | 0/93 |
| Pregnancy test false positiveInvestigations | 1/87 | 0/93 |
| Neuropathic painNervous system disorders | 1/87 | 1/93 |
| Sick sinus syndromeCardiac disorders | 1/87 | 0/93 |
| Event | Lenalidomide | Placebo to Lenalidomide |
|---|---|---|
| Rash NOSSkin and subcutaneous tissue disorders | 24/87 | 9/93 |
| NauseaGastrointestinal disorders | 14/87 | 15/93 |
| HeadacheNervous system disorders | 9/87 | 13/93 |
| FatigueGeneral disorders | 9/87 | 12/93 |
| Diarrhoea NOSGastrointestinal disorders | 11/87 | 10/93 |
| DizzinessNervous system disorders | 9/87 | 6/93 |
| PruritusSkin and subcutaneous tissue disorders | 8/87 | 4/93 |
| ConstipationGastrointestinal disorders | 8/87 | 5/93 |
| InsomniaPsychiatric disorders | 7/87 | 5/93 |
| Dry skinSkin and subcutaneous tissue disorders | 6/87 | 2/93 |
Safety population
| Age Continuous(years) | Lenalidomide | Placebo to Lenalidomide | Total |
|---|---|---|---|
| Mean | 43.9 ± 11.37 | 45.1 ± 11.06 | 44.5 ± 11.20 |
| Sex: Female, Male(Participants) | Lenalidomide | Placebo to Lenalidomide | Total |
|---|---|---|---|
| Female | 65 | 79 | 144 |
| Male | 22 | 14 | 36 |
| Race/Ethnicity, Customized(participants) | Lenalidomide | Placebo to Lenalidomide | Total |
|---|---|---|---|
| White | 81 | 86 | 167 |
| Black | 3 | 4 | 7 |
| Hispanic | 1 | 3 | 4 |
| Asian/Pacific Islander | 2 | 0 | 2 |
The record gives a start of Feb 2005, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 5 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenalidomide
Reflex Sympathetic Dystrophy →